The monogenetic disease epidermolysis bullosa (EB) is characterised by the formation of
extended blisters and lesions on the patient's skin upon minimal mechanical stress. Causal …

Background Epidermolysis bullosa (EB) is a rare, genetically and clinically heterogeneous
group of skin fragility disorders. No cure is currently available, but many novel and …

Abstract We present Dystrophic Epidermolysis Bullosa Cell Therapy (DEBCT), a scalable
platform producing autologous organotypic iPS cell-derived induced skin composite (iSC) …

Junctional epidermolysis bullosa (JEB) is a debilitating hereditary skin disorder caused by
mutations in genes encoding laminin-332, type XVII collagen (C17), and integrin-α6β4 …

Gene therapy based on the CRISPR/Cas9 system has emerged as a promising strategy for
treating the monogenic fragile skin disorder recessive dystrophic epidermolysis bullosa …

Magnet-mediated gene therapy has gained considerable interest from researchers as a
novel alternative for treating genetic disorders, particularly through the use of …

Gene editing facilitated by homology-directed repair (HDR) holds great potential for treating
monogenetic disorders such as recessive dystrophic epidermolysis bullosa (RDEB) …

Epidermolysis bullosa is a genetic skin disorder characterized by blister formation from
mechanical trauma. Dystrophic epidermolysis bullosa (DEB) is caused by mutations in the …

Epidermolysis bullosa (EB) is a heterogeneous group of genodermatoses characterized by
mucocutaneous blistering, resulting from intraepidermal or dermo-epidermal tissue …

Junctional epidermolysis bullosa (JEB) is a severe blistering skin disease caused by
mutations in genes encoding structural proteins essential for skin integrity. In this study, we …